ExodusPoint Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

ExodusPoint Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.57M	Buy	177,274 +157,213	+784%	+$2.53M	0.03%	546
2025 Q4	$324K	Buy	+20,061	New	+$266K	﹤0.01%	1291
2024 Q2	–	Sell	-14,467	Closed	-$172K	–	1753
2024 Q1	$172K	Buy	+14,467	New	+$193K	﹤0.01%	1373
2023 Q4	–	Sell	-34,393	Closed	-$331K	–	1762
2023 Q3	$331K	Buy	34,393 +3,213	+10%	+$32.8K	﹤0.01%	1386
2023 Q2	$281K	Buy	+31,180	New	+$287K	﹤0.01%	1566
2021 Q4	–	Sell	-19,173	Closed	-$335K	–	2388
2021 Q3	$335K	Buy	+19,173	New	+$389K	﹤0.01%	1573
2019 Q4	–	Sell	-13,600	Closed	-$158K	–	1708
2019 Q3	$158K	Buy	+13,600	New	+$220K	0.01%	1176
2019 Q2	–	Sell	-23,253	Closed	-$666K	–	1226
2019 Q1	$666K	Buy	+23,253	New	+$504K	0.05%	263

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's KALV Position: Q1 2026 in Review

ExodusPoint Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 784% in Q1 2026, buying an estimated $2.53M and bringing the position to 177,274 shares worth $3.57M. The position accounts for 0.03% of the portfolio, ranked #546.

ExodusPoint Capital Management first reported a position in KALV in Q1 2019 and has held it in 8 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

ExodusPoint Capital Management held 177,274 shares of KalVista Pharmaceuticals worth $3.57M as of Q1 2026.
ExodusPoint Capital Management bought 157,213 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.53M.
KalVista Pharmaceuticals made up 0.03% of ExodusPoint Capital Management's portfolio in Q1 2026, its #546 holding.
ExodusPoint Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2019 and has held it in 8 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.